Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)

被引：11

作者：

Facchinetti, Francesco ^{[1
]}

Pilotto, Sara ^{[2
]}

Metro, Giulio ^{[3
]}

Baldini, Editta ^{[4
]}

Bertolaccini, Luca ^{[5
]}

Cappuzzo, Federico ^{[6
]}

Delmonte, Angelo ^{[7
]}

Gasparini, Stefano ^{[8
,9
]}

Inno, Alessandro ^{[10
]}

Marchetti, Antonio ^{[11
]}

Passiglia, Francesco ^{[12
]}

Puma, Francesco ^{[13
]}

Ricardi, Umberto ^{[14
]}

Rossi, Antonio ^{[15
]}

Crino, Lucio ^{[7
]}

Novellol, Silvia ^{[12
]}

机构：

[1] Univ Paris Saclay, INSERM, U981, Gustave Roussy Canc Campus, Villejuif, France

[2] Univ Verona, Verona Univ Hosp, Med Oncol, Verona, Italy

[3] Azienda Osped Perugia, Santa Maria Misericordia Hosp, Med Oncol, Perugia, Italy

[4] S Luca Hosp, Dept Oncol, Lucca, Italy

[5] IRCCS, European Inst Oncol, IEO, Div Thorac Surg, Milan, Italy

[6] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy

[7] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[8] Polytech Univ Marche Reg, Dept Biol Sci & Publ Hlth, Ancona, Italy

[9] Azienda Osped Riuniti, Pulm Dis Unit, Ancona, Italy

[10] IRCCS Osped Sacro Cuore Don Calabria, Med Oncol, Verona, Italy

[11] Ctr Excellence Aging Univ Fdn, Ctr Predict Mol Med, Chieti, Italy

[12] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, Italy

[13] Univ Perugia, S Maria Misericordia Hosp, Div Thorac Surg, Med Sch, Perugia, Italy

[14] Univ Torino, Dept Oncol, Radiat Oncol, Turin, Italy

[15] Fdn IRCCS Casa Sollievo Sofferenza, Div Med Oncol, Foggia, Italy

来源：

TUMORI JOURNAL | 2019年 / 105卷

关键词：

AIOM; non-small cell lung cancer; guidelines; recommendations; RANDOMIZED PHASE-III; PACLITAXEL PLUS CARBOPLATIN; PLATINUM-BASED CHEMOTHERAPY; TYROSINE KINASE INHIBITORS; FACTOR RECEPTOR MUTATIONS; UNCOMMON EGFR MUTATIONS; WILD-TYPE EGFR; OPEN-LABEL; 1ST-LINE TREATMENT; ELDERLY-PATIENTS;

D O I：

10.1177/0300891619857418

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment landscape of metastatic non-small cell lung cancer (NSCLC) has dramatically evolved in recent years, since the recognition of several clinical-biological entities requiring personalized treatment approaches, leading to significant improvements in patients' survival outcomes. In particular, targeted therapies acting against EGFR, ALK, and ROS1, and immunotherapeutic agents modulating the PD-1/PD-L1 axis, represent new milestones in the treatment of advanced disease, supporting a chemotherapy backbone within a multidisciplinary model. The Italian Association of Medical Oncology (AIOM) has developed evidence-based guidelines for the management of lung tumors. Given the epidemiologic relevance, this report is dedicated to the treatment of advanced/metastatic NSCLC. These guidelines serve as a practical tool for oncologists, physicians, and other healthcare professionals to easily embrace the updated key points of NSCLC treatment strategies. Considering the upcoming introduction of potential new standards of care in several disease settings, these guidelines represent a benchmark from which to move forward.

引用

页码：3 / 14

页数：12

共 105 条

[21] Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group [J].

Fossella, F ;

Pereira, JR ;

von Pawel, J ;

Pluzanska, A ;

Gorbounova, V ;

Kaukel, E ;

Mattson, KV ;

Ramlau, R ;

Szczesna, A ;

Fidias, P ;

Millward, M ;

Belani, CP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3016-3024

[22] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[23] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[24] Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial [J].

Garassino, Marina Chiara ;

Martelli, Olga ;

Broggini, Massimo ;

Farina, Gabriella ;

Veronese, Silvio ;

Rulli, Eliana ;

Bianchi, Filippo ;

Bettini, Anna ;

Longo, Flavia ;

Moscetti, Luca ;

Tomirotti, Maurizio ;

Marabese, Mirko ;

Ganzinelli, Monica ;

Lauricella, Calogero ;

Labianca, Roberto ;

Floriani, Irene ;

Giaccone, Giuseppe ;

Torri, Valter ;

Scanni, Alberto ;

Marsoni, Silvia .

LANCET ONCOLOGY, 2013, 14 (10) :981-988

[25] Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study [J].

Gobbini, Elisa ;

Galetta, Domenico ;

Tiseo, Marcello ;

Graziano, Paolo ;

Rossi, Antonio ;

Bria, Emilio ;

Di Maio, Massimo ;

Rossi, Giulio ;

Gregorc, Vanesa ;

Riccardi, Ferdinando ;

Scotti, Vieri ;

Ceribelli, Anna ;

Buffoni, Lucio ;

Delmonte, Angelo ;

Franchina, Tindara ;

Migliorino, Maria Rita ;

Cortinovis, Diego ;

Pisconti, Salvatore ;

Bordi, Paola ;

Catino, Annamaria ;

Maiello, Evaristo ;

Arizio, Francesca ;

Novello, Silvia .

LUNG CANCER, 2017, 111 :30-37

[26]

Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66

[27] Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial [J].

Gridelli, C ;

Perrone, F ;

Gallo, C ;

Cigolari, S ;

Rossi, A ;

Piantedosi, F ;

Barbera, S ;

Ferraù, F ;

Piazza, E ;

Rosetti, F ;

Clerici, M ;

Bertetto, O ;

Robbiati, SF ;

Frontini, L ;

Sacco, C ;

Castiglione, F ;

Favaretto, A ;

Novello, S ;

Migliorino, MR ;

Gasparini, G ;

Galetta, D ;

Iaffaioli, RV ;

Gebbia, V .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) :362-372

[28] Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials [J].

Gridelli, Cesare ;

Morabito, Alessandro ;

Cavanna, Luigi ;

Luciani, Andrea ;

Maione, Paolo ;

Bonanno, Laura ;

Filipazzi, Virginio ;

Leo, Silvana ;

Cinieri, Saverio ;

Ciardiello, Fortunato ;

Burgio, Marco Angelo ;

Bilancia, Domenico ;

Cortinovis, Diego ;

Rosetti, Francesco ;

Bianco, Roberto ;

Gebbia, Vittorio ;

Artioli, Fabrizio ;

Bordonaro, Roberto ;

Fregoni, Vittorio ;

Mencoboni, Manlio ;

Nelli, Fabrizio ;

Riccardi, Ferdinando ;

di Isernia, Giuditta ;

Costanzo, Raffaele ;

Rocco, Gaetano ;

Daniele, Gennaro ;

Signoriello, Simona ;

Piccirillo, Maria Carmela ;

Gallo, Ciro ;

Perrone, Francesco .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (25) :2585-+

[29] First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung [J].

Han, Ji-Youn ;

Park, Keunchil ;

Kim, Sang-We ;

Lee, Dae Ho ;

Kim, Hyae Young ;

Kim, Heung Tae ;

Ahn, Myung Ju ;

Yun, Tak ;

Ahn, Jin Seok ;

Suh, Cheolwon ;

Lee, Jung-Shin ;

Yoon, Sung Jin ;

Han, Jong Hee ;

Lee, Jae Won ;

Jo, Sook Jung ;

Lee, Jin Soo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1122-1128

[30] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

← 1 2 3 4 5 6 7 8 9 10 →